Hillevax Inc
HLVX2.060USD
+0.020+0.98%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
103.21MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Hillevax Inc Unternehmen
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Unternehmensinformationen
BörsenkürzelHLVX
Name des UnternehmensHillevax Inc
IPO-datumApr 29, 2022
CEODr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Anzahl der mitarbeiter14
WertpapierartOrdinary Share
GeschäftsjahresendeApr 29
Addresse321 Harrison Ave, Suite 500
StadtBOSTON
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02118
Telefon16172135054
Websitehttps://www.hillevax.com/
BörsenkürzelHLVX
IPO-datumApr 29, 2022
CEODr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
876.86K
+11.51%
Mr. Jaime Sepulveda, M.D.
Mr. Jaime Sepulveda, M.D.
Independent Director
Independent Director
59.22K
+40.93%
Ms. Jeryl Hilleman
Ms. Jeryl Hilleman
Independent Director
Independent Director
59.22K
+40.93%
Mr. Shane Maltbie, CPA
Mr. Shane Maltbie, CPA
Chief Financial Officer
Chief Financial Officer
38.30K
-52.06%
Dr. Gary Dubin, M.D.
Dr. Gary Dubin, M.D.
Independent Director
Independent Director
17.20K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Lead Independent Director
Lead Independent Director
17.20K
--
Dr. Nanette Cocero, Ph.D.
Dr. Nanette Cocero, Ph.D.
Independent Director
Independent Director
17.20K
--
Dr. Shelley Chu, M.D., Ph.D.
Dr. Shelley Chu, M.D., Ph.D.
Independent Director
Independent Director
17.20K
--
Dr. Aditya Kohli, Ph.D.
Dr. Aditya Kohli, Ph.D.
Director
Director
--
--
Dr. Julie Louise Gerberding, M.D.
Dr. Julie Louise Gerberding, M.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
876.86K
+11.51%
Mr. Jaime Sepulveda, M.D.
Mr. Jaime Sepulveda, M.D.
Independent Director
Independent Director
59.22K
+40.93%
Ms. Jeryl Hilleman
Ms. Jeryl Hilleman
Independent Director
Independent Director
59.22K
+40.93%
Mr. Shane Maltbie, CPA
Mr. Shane Maltbie, CPA
Chief Financial Officer
Chief Financial Officer
38.30K
-52.06%
Dr. Gary Dubin, M.D.
Dr. Gary Dubin, M.D.
Independent Director
Independent Director
17.20K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Lead Independent Director
Lead Independent Director
17.20K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Tue, Jul 29
Aktualisiert: Tue, Jul 29
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Frazier Life Sciences Management, L.P.
21.17%
Takeda Pharmaceutical Co Ltd
13.41%
Tang Capital Management, LLC
9.81%
EcoR1 Capital, LLC
5.77%
Lightspeed Venture Partners
4.59%
Other
45.24%
Aktionäre
Aktionäre
Anteil
Frazier Life Sciences Management, L.P.
21.17%
Takeda Pharmaceutical Co Ltd
13.41%
Tang Capital Management, LLC
9.81%
EcoR1 Capital, LLC
5.77%
Lightspeed Venture Partners
4.59%
Other
45.24%
Aktionärstypen
Aktionäre
Anteil
Private Equity
22.82%
Hedge Fund
16.80%
Investment Advisor/Hedge Fund
15.22%
Corporation
13.41%
Investment Advisor
11.56%
Venture Capital
9.11%
Individual Investor
3.71%
Research Firm
1.02%
Bank and Trust
0.08%
Other
6.27%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
224
44.13M
88.00%
-14.24M
2025Q1
229
46.31M
92.39%
-14.77M
2024Q4
226
47.12M
94.62%
-13.67M
2024Q3
218
46.00M
92.53%
-13.52M
2024Q2
202
49.77M
100.23%
-2.02M
2024Q1
182
48.47M
97.79%
-558.66K
2023Q4
166
46.57M
96.99%
+4.81M
2023Q3
161
39.77M
86.30%
+8.72M
2023Q2
146
30.99M
80.52%
+1.24M
2023Q1
140
32.25M
85.25%
+3.76M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Frazier Life Sciences Management, L.P.
10.62M
21.17%
--
--
Mar 31, 2025
Takeda Pharmaceutical Co Ltd
6.72M
13.41%
--
--
Mar 31, 2025
Tang Capital Management, LLC
4.92M
9.81%
--
--
May 02, 2025
Lightspeed Venture Partners
2.30M
4.59%
-37.51K
-1.60%
Mar 31, 2025
Franklin Advisers, Inc.
1.95M
3.9%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.92M
3.82%
-70.63K
-3.56%
Mar 31, 2025
Deerfield Management Company, L.P.
1.88M
3.75%
--
--
Mar 31, 2025
Abingworth Management Limited
1.84M
3.67%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.59M
3.16%
-20.50K
-1.28%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
Fidelity MSCI Health Care Index ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Global X Russell 2000 ETF
0%
Avantis Responsible US Equity ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Mehr Anzeigen
iShares Micro-Cap ETF
Anteil0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
Anteil0%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0%
Fidelity MSCI Health Care Index ETF
Anteil0%
Fidelity Nasdaq Composite Index ETF
Anteil0%
Global X Russell 2000 Covered Call ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
Avantis Responsible US Equity ETF
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
ProShares Ultra Nasdaq Biotechnology
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
